Provided by Tiger Fintech (Singapore) Pte. Ltd.

ATAI Life Sciences B.V.*

1.48
+0.09006.47%
Post-market: 1.500.0200+1.35%19:56 EDT
Volume:1.44M
Turnover:2.12M
Market Cap:287.12M
PE:-1.86
High:1.52
Open:1.42
Low:1.42
Close:1.39
Loading ...

Company Profile

Company Name:
ATAI Life Sciences B.V.*
Exchange:
NASDAQ
Establishment Date:
2018
Employees:
83
Office Location:
Wallstrasse 16,Berlin,Berlin,Germany
Zip Code:
10179
Fax:
49 89 2153 90351
Introduction:
Atai Life Sciences N.V., a clinical-stage biopharmaceutical company, develops and invests in various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Its product candidates include COMP360, a proprietary psilocybin which is in Phase 3 program; BPL-003, an intranasal formulation that is in Phase 2a and 2b clinical studies; TRD; VLS-01, an transmucosal film in Phase 1b clinical studies; and ELE-101, a serotonergic psychedelic that is in Phase 1/2a study, for the treatment of treatment resistant depression. The company also develop IBX-210, an intravenous formulation of ibogaine, and DMX-1002, an oral formulation of ibogaine indicated for the treatment of opioid use disorder; EMP-01, an oral formulation of an R-MDMA derivative being developed for the treatment of post-traumatic stress disorder; and EGX-A and EGX-B, psychedelic-like with novel, non-tryptamine structures with differentiated 5-HT receptor pharmacology. In addition, it offers RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator for cognitive impairment associated with schizophrenia; and GRX-917, a deuterated etifoxine for the treatment of generalize anxiety disorder. Further, the company develops PCN-101, a subcutaneous formulation of R-ketamine, as a therapy for psychiatric indications initially focused on TRD; KUR-101, a formulation of deuterated mitragynine for the treatment of OUD; and RLS-01, indicated for treatment resistant depression. ATAI Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany with offices in New York and London.

Directors

Name
Position
Christian Angermayer
Supervisory Director,Chairman
Alexis de Rosnay
Supervisory Director
Amir Kalali
Supervisory Director
Andrea Heslin Smiley
Supervisory Director
Jason Camm
Supervisory Director
Michael Auerbach
Supervisory Director
Sabrina Martucci Johnson
Supervisory Director

Shareholders

Name
Position
Florian Brand
Co-Founder and Chief Executive Officer
Stephen Bardin
Chief Financial Officer
Rolando Gutierrez Esteinou
Chief Medical Officer
Srinivas Rao
Co-Founder and Chief Scientific Officer